Blogs

Personalised Medicine

Over the years, there has been a gradual paradigm shift from traditional medicine as a result of increase in scientific knowledge. The traditional path of drug development which has conventionally influenced the practice of medicine has been based on identifying therapies which target an entire population. However, there has been the recognition of patients bearing distinctive inherent traits which cause variations in response to therapy and subsequently tailoring medicines toward these unique responses. It is in this light that personalised medicine evolved which is the tailoring of treatment to the unique molecular or genetic mapping of individual patients and how these unique features contribute to the occurrence of certain disease pattern and progression. The prospect of personalised medicine being an integral part of detecting, managing and preventing diseases is primarily dependent on its progress and impact of personalised medicine in field medicine. Progress has been seen in areas such as ongoing genomic projects, merging translational medicine with personalised medicine, increasing advance toward personal genetic testing, and the observed evolution of conventional medicine to personalised medicine. 

The global personalised medicine (PM) market size was estimated at USD 1.57 trillion in 2018 and is anticipated to expand at a CAGR of 10.6% to USD 3.18 trillion by 2025. Growing number of approved companion diagnostics and biomarker products have been proved promising avenues for the development of advanced precision diagnostic tests. Several personalised diagnostics and therapeutic products based on companion diagnostics are under clinical trials and development pipelines, which also add an incremental opportunity to accelerate this market.

Keynote Connect | Medical Conference | Healthcare Workshop | Medicine Event | Accademic Conference | CME Conference | Personalised Medicine Conference